Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: Tislelizumab （neoadjuvant）; Drug: Cisplatin （neoadjuvant）; Drug: Nab-paclitaxel （neoadjuvant）; Procedure: Surgical resection; Drug: Cisplatin（adjuvant）; Drug: Tislelizumab（adjuvant）; Radiation: Radiation; Drug: Carboplatin（neoadjuvant）; Drug: Carboplatin（adjuvant） Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials